Medical Articles

Sea Cucumber Extract TBL-12 Correlative Studies on the Anticancer Effects

Multiple myeloma is a cancer that evolves from a state known as Monoclonal Gammopathy of Undetermined Significance (MGUS), defined by parameters of M spike and bone marrow. After evolution to myeloma, patients may be asymptomatic, that is, without any endorgan disease of hypercalcemia, renal insufficiency, and anemia or bone lesions. In asymptomatic myeloma (ASxM), there is no standard therapy. Thalidomide has been tried in patients with ASxM but with significant toxicity.

Suppression of Human Multiple Myeloma Cell Growth by TBL-12 in Combination with low doses of Velcade: Insight in to the modulation of IL-6/STAT-3 mechanisms

Multiple myeloma (MM) is characterized by the latent accumulation of plasma cells in the bone marrow. As the side effects due to drugs that are currently in use are largely complex, targeting MM with natural agents in combination with FDA approved drugs seems to be a novel approach to overcome the side effects.

Synergistic Suppression of Human Multiple Myeloma Cell Growth by the Natural Product TBL-12 in Combination with Low Doses of Velcade: Insight Into Mechanisms

Targeting Multiple Myeloma (MM) cells with potential natural agents could overcome the side effects of current treatment drugs while increasing the efficacy at very low doses. In this study we tested the efficacy of proteasome inhibitor Velcade (Bortezomib) with TBL-12, (an extract from Sea Cucumber, Unicorn Pacific Corporation) in human myeloma cells.

A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients with Untreated Asymptomatic Myeloma

Background: Patients with smoldering multiple myeloma (MM) may remain asymptomatic (ASx) for variable amounts of time and are therefore typically monitored without treatment. Chemoprevention trials using thalidomide have found the toxicity to be prohibitive and longer follow up is needed for the early systemic treatment with lenalidomide and dexamethasone of high risk ASxMM.

A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients with Untreated Asymptomatic Myeloma Mount Sinai School of Medicine

Abstract

Sphingolipids/glycosides contained in sea cucumbers have been shown preclinically to have a number of antitumor properties, including the inhibition of osteoclastogenesis. In this pilot phase II trial, a  total of 20 patients with high risk asymptomatic multiple myeloma (ASxMM) were given 40 ml of the sea cucumber abstract TBL12 twice daily.

A Phase II Trial of TBL 12 Sea Cucumber Extract In Patients with Untreated Asymptomatic Myeloma

Patients with smoldering multiple myeloma (MM) may remain asymptomatic(ASx) for variable amounts of time and are therefore typicallymonitored without treatment. Chemoprevention trials using thalidomidefound prohibitive toxicity and longer follow up is needed forearly systemic treatment with lenalidomide/dexamethasone ofhigh risk ASxMM.

Subscribe to RSS - Medical Articles

The Benefits

YOUR IMMUNE SYSTEM

This natural product, with no known side effects, that improves both your immune system and quality of life.

more >

The Research

PROVEN RESULTS

The first natural product to be granted orphan drug indication for the treatment of Multiple Myeloma by the FDA. Discover the findings from some of the best scientists in the world.

more >

THE PROCESS

SIMPLE & SAFE

TBL-12 is a natural product made out of marine ingredients, with no known side effects. All you need to do is melt the frozen product and consume your required dose daily.

more >